Kaoru Tamura

Title: Kaoru Tamura: Innovator in Oncolytic Virus Therapy

Introduction

Kaoru Tamura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer treatment through his innovative work on oncolytic virus therapy. With a total of 2 patents, Tamura is recognized for his groundbreaking research aimed at combating resistant tumors.

Latest Patents

Tamura's latest patents focus on a recombinant oncolytic virus that comprises a nucleic acid sequence encoding tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). One such oncolytic virus is oHSV. The patent details various forms of TRAIL contained within the oncolytic virus, including a secreted form of TRAIL. Additionally, the patent discloses host cells and therapeutic formulations that incorporate the recombinant oncolytic virus. Methods of treating cancer in a subject by administering a therapeutic formulation comprising the recombinant oncolytic virus are also outlined.

Career Highlights

Kaoru Tamura is affiliated with The General Hospital Corporation, where he continues to advance his research in oncolytic virus therapy. His work has garnered attention for its potential to improve treatment outcomes for patients with resistant tumors.

Collaborations

Tamura collaborates with notable colleagues in the field, including Khalid Shah and Hiroaki Wakimoto. Their combined expertise contributes to the innovative research being conducted at The General Hospital Corporation.

Conclusion

Kaoru Tamura's contributions to oncolytic virus therapy represent a significant advancement in cancer treatment. His innovative patents and collaborative efforts highlight the importance of research in developing effective therapies for resistant tumors.